Charles River Laboratories International, Inc. (CRL) stock
CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30225% above fair value
$333.25+1.09 (+0.33%)
Close on Nov 18, 2026Market cap $15.91BP/E –Yield –
Charles River Laboratories International operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Charles River Laboratories International's operating cash flow for the twelve months ending Jun 27, 2026 was $582.15M, down 26.1% year over year. For fiscal 2025 it was $737.65M, up 0.4% from the year before. Over ten years it grew 9.2% a year on average. The highest annual figure on record is $760.80M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $737.65M | +0.4% |
| FY2024 | Dec 28, 2024 | $734.58M | +7.4% |
| FY2023 | Dec 30, 2023 | $683.90M | +10.4% |
| FY2022 | Dec 31, 2022 | $619.64M | -18.6% |
| FY2021 | Dec 25, 2021 | $760.80M | +39.2% |
| FY2020 | Dec 26, 2020 | $546.58M | +13.6% |
| FY2019 | Dec 28, 2019 | $480.94M | +9.0% |
| FY2018 | Dec 29, 2018 | $441.14M | +38.7% |
| FY2017 | Dec 30, 2017 | $318.07M | +0.4% |
| FY2016 | Dec 31, 2016 | $316.90M | +3.3% |
| FY2015 | Dec 26, 2015 | $306.83M | +21.7% |
| FY2014 | Dec 27, 2014 | $252.13M | +20.6% |
| FY2013 | Dec 28, 2013 | $209.05M | +0.5% |
| FY2012 | Dec 29, 2012 | $208.01M | +0.6% |
| FY2011 | Dec 31, 2011 | $206.84M | +22.9% |
| FY2010 | Dec 25, 2010 | $168.24M | -22.0% |
| FY2009 | Dec 26, 2009 | $215.58M | -21.8% |
| FY2008 | Dec 27, 2008 | $275.57M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 27, 2026 | $179.73M | -12.2% |
| Q1 FY2026 | Mar 28, 2026 | $41.08M | -76.1% |
| Q4 FY2025 | Dec 27, 2025 | $147.52M | -7.4% |
| Q3 FY2025 | Sep 27, 2025 | $213.83M | -15.1% |
| Q2 FY2025 | Jun 28, 2025 | $204.60M | +5.7% |
| Q1 FY2025 | Mar 29, 2025 | $171.70M | +32.2% |
| Q4 FY2024 | Dec 28, 2024 | $159.36M | -27.9% |
| Q3 FY2024 | Sep 28, 2024 | $251.79M | +22.6% |
| Q2 FY2024 | Jun 29, 2024 | $193.54M | +30.7% |
| Q1 FY2024 | Mar 30, 2024 | $129.89M | +18.7% |
| Q4 FY2023 | Dec 30, 2023 | $220.94M | -5.9% |
| Q3 FY2023 | Sep 30, 2023 | $205.45M | +54.7% |
| Q2 FY2023 | Jul 1, 2023 | $148.12M | -0.9% |
| Q1 FY2023 | Apr 1, 2023 | $109.38M | +6.6% |
| Q4 FY2022 | Dec 31, 2022 | $234.76M | +2.4% |
| Q3 FY2022 | Sep 24, 2022 | $132.78M | -24.0% |
| Q2 FY2022 | Jun 25, 2022 | $149.47M | -19.9% |
| Q1 FY2022 | Mar 26, 2022 | $102.63M | -39.7% |
| Q4 FY2021 | Dec 25, 2021 | $229.26M | +65.7% |
| Q3 FY2021 | Sep 25, 2021 | $174.72M | -1.5% |
| Q2 FY2021 | Jun 26, 2021 | $186.59M | +15.0% |
| Q1 FY2021 | Mar 27, 2021 | $170.23M | +148.2% |
| Q4 FY2020 | Dec 26, 2020 | $138.38M | -23.4% |
| Q3 FY2020 | Sep 26, 2020 | $177.30M | +13.8% |
| Q2 FY2020 | Jun 27, 2020 | $162.31M | +25.3% |
| Q1 FY2020 | Mar 28, 2020 | $68.59M | +361.6% |
| Q4 FY2019 | Dec 28, 2019 | $180.68M | +29.1% |
| Q3 FY2019 | Sep 28, 2019 | $155.85M | +32.9% |
| Q2 FY2019 | Jun 29, 2019 | $129.55M | +4.6% |
| Q1 FY2019 | Mar 30, 2019 | $14.86M | -75.3% |
| Q4 FY2018 | Dec 29, 2018 | $139.97M | +12.7% |
| Q3 FY2018 | Sep 29, 2018 | $117.24M | +97.1% |
| Q2 FY2018 | Jun 30, 2018 | $123.87M | +23.5% |
| Q1 FY2018 | Mar 31, 2018 | $60.05M | +76.5% |
| Q4 FY2017 | Dec 30, 2017 | $124.24M | +4.7% |
| Q3 FY2017 | Sep 30, 2017 | $59.49M | -17.7% |
| Q2 FY2017 | Jul 1, 2017 | $100.32M | – |
| Q1 FY2017 | Apr 1, 2017 | $34.03M | – |
| Q4 FY2016 | Dec 31, 2016 | $118.65M | – |
| Q3 FY2016 | Sep 24, 2016 | $72.30M | – |
See a number that looks wrong?